Effect of Acidic Formulation, Beverage, or Grapefruit Juice on Acalabrutinib PK

Phase 1, randomised, open-label trial of acalabrutinib tablet (Variant 1) in mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) (3 arms), sponsored by Acerta Pharma. Primary endpoints: Area Under the Plasma Concentration-time Curve From Time 0 to Time of Last Measurable Concentration of ACP-196, Area Under the Plasma Concentration-time Curve From Time 0 to Infinity of ACP-196 and 1 more. Started Jan 2016; status: completed.